G Des Guetz

Summary

Country: France

Publications

  1. ncbi Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX
    G Des Guetz
    Department of Oncology, Avicenne Hospital, Bodigny, France
    Anticancer Res 30:4297-301. 2010
  2. ncbi Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer
    G Des Guetz
    Department of Oncology, Avicenne Hospital, 93009 Bobigny, France
    Anticancer Res 27:2715-9. 2007
  3. ncbi Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, Bobigny, France
    Eur J Cancer 45:1890-6. 2009
  4. ncbi Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, 125 route de Stalingrad, 93009 Bobigny, France
    Anticancer Res 29:1615-20. 2009
  5. ncbi Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
    H C A Graat
    Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 94:1837-44. 2006
  6. ncbi [Biotherapy in colorectal cancer]
    G Des Guetz
    Service d Oncologie Medicale, Hôpital Avicenne Bobigny
    J Chir (Paris) 142:291-6. 2005
  7. ncbi [NSAID, type 2 cyclo-oxygenase inhibitors and pancreatic carcinogenesis]
    Gaetan des Guetz
    Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
    Gastroenterol Clin Biol 29:411-4. 2005
  8. ncbi [Colorectal cancer in elderly patients]
    G Des Guetz
    Service d Oncologie, Hopital Avicenne, 125, rue de Stalingrad, 93009 Bobigny Cedex, France
    Rev Med Suisse 5:1116-8, 1120, 1122-3. 2009
  9. ncbi Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis
    Gaetan des Guetz
    AP HP, Department of Oncology, Avicenne Hospital, 125 route de Stalingrad, 93009 Bobigny, France
    Eur J Cancer 46:1049-55. 2010
  10. ncbi Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, 125 route de Stalingrad, 93009, Bobigny, France
    Target Oncol 4:57-62. 2009

Detail Information

Publications21

  1. ncbi Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX
    G Des Guetz
    Department of Oncology, Avicenne Hospital, Bodigny, France
    Anticancer Res 30:4297-301. 2010
    ..Colorectal cancer (CRC) patients whose tumours have microsatellite instability (MSI) do not benefit from adjuvant 5-fluorouracil. However, the predictive value of MSI is not known for FOLFOX, now recommended in adjuvant setting...
  2. ncbi Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer
    G Des Guetz
    Department of Oncology, Avicenne Hospital, 93009 Bobigny, France
    Anticancer Res 27:2715-9. 2007
    ..A current treatment of reference for colon cancer is a combination of 5-FU and oxaliplatin (FOLFOX). The aim of this study was to determine the efficiency of the FOLFOX treatment in patients with metastatic MSI colon cancer...
  3. ncbi Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, Bobigny, France
    Eur J Cancer 45:1890-6. 2009
    ..Microsatellite instability (MSI) status in predicting the efficacy of adjuvant chemotherapy in colorectal cancer remains controversial...
  4. ncbi Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, 125 route de Stalingrad, 93009 Bobigny, France
    Anticancer Res 29:1615-20. 2009
    ..A previous meta-analysis (MA) in the adjuvant setting showed that MSI-high (H) status did not predict the efficacy of chemotherapy. The predictive value of MSI status on the effect of metastatic chemotherapy was investigated by MA...
  5. ncbi Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
    H C A Graat
    Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 94:1837-44. 2006
    ..In general, our work underscores the importance of testing new genetic anticancer agents and treatment regimens on primary cancer specimens...
  6. ncbi [Biotherapy in colorectal cancer]
    G Des Guetz
    Service d Oncologie Medicale, Hôpital Avicenne Bobigny
    J Chir (Paris) 142:291-6. 2005
    ..EGF is a major cell growth factor. The side effects of these new biotherapies are different from chemotherapy: bevacizumab affects vascular elements and the most common side effect of anti-EGFR treatment is acneiform skin rash...
  7. ncbi [NSAID, type 2 cyclo-oxygenase inhibitors and pancreatic carcinogenesis]
    Gaetan des Guetz
    Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
    Gastroenterol Clin Biol 29:411-4. 2005
  8. ncbi [Colorectal cancer in elderly patients]
    G Des Guetz
    Service d Oncologie, Hopital Avicenne, 125, rue de Stalingrad, 93009 Bobigny Cedex, France
    Rev Med Suisse 5:1116-8, 1120, 1122-3. 2009
    ..This is a review of the different stages of care for elderly patients with colorectal cancer in the light of recent publications...
  9. ncbi Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis
    Gaetan des Guetz
    AP HP, Department of Oncology, Avicenne Hospital, 125 route de Stalingrad, 93009 Bobigny, France
    Eur J Cancer 46:1049-55. 2010
    ..In stage III colorectal cancer (CRC), adjuvant chemotherapy (CT) is usually prescribed within two months after curative surgery. Whether or not delaying initiation of CT affects survival is still debated...
  10. ncbi Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Gaetan des Guetz
    Department of Oncology, APHP, Hopital Avicenne, 125 route de Stalingrad, 93009, Bobigny, France
    Target Oncol 4:57-62. 2009
    ..83 (95% confidence interval: 0.95; 0.65-1.05; p = 0.11). In conclusion, MSI status did not predict the effect of chemotherapy for metastatic CRC. Metastatic chemotherapy had a similar effect on both MSI-H or on MSS tumors...
  11. ncbi Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
    J J Mourad
    Avicenne Hospital Assistance Publique Hôpitaux de Paris, Paris XIII University EA3412, Bobigny, France
    Ann Oncol 19:927-34. 2008
    ..05). Thus, bevacizumab treatment resulted in endothelial dysfunction and capillary rarefaction; both changes are closely associated and could be responsible for the rise in BP observed in most patients...
  12. ncbi Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value
    A Tadlaoui Hbibi
    Universite Paris 13, EA 3406, Bobigny, France
    Cancer Biomark 4:83-91. 2008
    ....
  13. ncbi Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
    G Des Guetz
    APHP Department of Oncology, Hopital Avicenne, Bobigny, France
    Br J Cancer 94:1823-32. 2006
    ..g. antiangiogenic therapy). Assessment of these angiogenic markers should be better standardised in future studies...
  14. ncbi [Single-center cohort study of elderly patients with surgically removed colorectal cancers]
    G Des Guetz
    Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
    Rev Med Suisse 6:1081-2, 1084-5. 2010
    ..002) Standard therapy was hardly applicable because many patients were frail. In the future, usefulness of participation to the staffs of a geriatrist will be assessed prospectively...
  15. ncbi Small bowel carcinoma revealing HNPCC syndrome
    T Babba
    Service de Gastroenterologie, Hopital Avicenne, 125, rue de Stalingrad, 93009 Bobigny Cedex, France
    Gastroenterol Clin Biol 34:325-8. 2010
    ..This report supports the systematic study of the MSI status in every patient with a small bowel carcinoma below 60-year-old of age in order to screen for HNPCC syndrome even in the absence of a family history of related cancers...
  16. ncbi F-18 FDG PET detection of a medullary thyroid carcinoma in a patient with metastatic colonic cancer; literature review
    R Cohen
    Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, Paris XIII University CRNH, 93009 Bobigny Cedex, France
    Ann Endocrinol (Paris) 70:468-72. 2009
    ..We report a case of a medullary thyroid carcinoma discovered by F-18 fluorodeoxyglucose-positron emission tomography (F-18 FDG PET)...
  17. ncbi [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]
    K Chouahnia
    Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
    Rev Mal Respir 23:149-51. 2006
    ..Carcinomatous meningitis is a major complication in Non Small Cell Lung Cancer (NSCLC). Despite treatment with radiotherapy alone or in combination with intrathecal and systemic chemotherapy, its prognosis remains poor...
  18. ncbi [Sunitinib and hypothyroidism]
    R Cohen
    Université Paris XIII CRNH et service de médecine interne et d endocrinologie, Hopital Avicenne, APHP, 93009 Bobigny Cedex, France
    Ann Endocrinol (Paris) 68:332-6. 2007
    ..This unique thyroid side effect of sunitinib with the non-visualisation of thyroid suggests a possible and promising antitumor activity in thyroid cancer...
  19. ncbi [39th congress of the American Society of Clinical Oncology]
    G Des Guetz
    , Institut Curie, Paris
    J Chir (Paris) 140:249-50. 2003
  20. ncbi Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy
    D Decaudin
    Ann Oncol 14:171-2. 2003
  21. ncbi [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]
    G Des Guetz
    , Institut Curie, Paris, France
    J Chir (Paris) 139:268-73. 2002
    ..This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors...